Yuan-Chao Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuan-Chao Zhu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Bo-Lin Zhu
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application, (Beijing Hospital)
1 shared publicationBolin Zhu
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, 100730, People's Republic of China
1 shared publicationDi Chen
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application, (Beijing Hospital)
1 shared publicationFei Zhao
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application, (Beijing Hospital)
1 shared publicationJianchun Li
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, 100730, People's Republic of China
1 shared publication- Liang Liang
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application, (Beijing Hospital)
1 shared publication
Latest Publications
- Open Access
- 31 August 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2551822
Risk factors of linezolid-associated hyponatremia from a retrospective case–control study: decreased serum albumin as a selective predictor in elder patients
The incidence of linezolid-associated hyponatremia is approximately 20% in real-world studies. However, there are limited case reports and rare research on linezolid-induced hyponatremia. This study aims to identify risk factors associated with linezolid-induced hyponatremia, particularly in older patients. This retrospective study was conducted from January 2018 to December 2023. Patients aged over 18 years who received linezolid for at least three days at Beijing Hospital were included. Statistical analyses were performed using SPSS Statistics version 19. 68 patients were identified in the hyponatremia group, with 68 matched individuals by sex and age in the control group. Binary logistic regression analysis revealed that a history of cardiovascular disease, estimated glomerular filtration rate, and the duration of linezolid therapy were risk factors for hyponatremia. Subgroup analysis in patients age ≥ 65 identified the duration of therapy, a history of cardiovascular disease, a history of endocrine diseases, and serum albumin (ALB) decreased during linezolid therapy as key indicators of hyponatremia. A decrease in ALB during linezolid therapy is a more selective predictor of hyponatremia than baseline ALB. Linezolid-induced hyponatremia is associated with adverse outcomes, highlighting the importance of monitoring serum sodium and ALB in patients receiving this therapy.
- 31 August 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2551822
Open AccessRisk factors of linezolid-associated hyponatremia from a retrospective case–control study: decreased serum albumin as a selective predictor in elder patients
The incidence of linezolid-associated hyponatremia is approximately 20% in real-world studies. However, there are limited case reports and rare research on linezolid-induced hyponatremia. This study aims to identify risk factors associated with linezolid-induced hyponatremia, particularly in older patients. This retrospective study was conducted from January 2018 to December 2023. Patients aged over 18 years who received linezolid for at least three days at Beijing Hospital were included. Statistical analyses were performed using SPSS Statistics version 19. 68 patients were identified in the hyponatremia group, with 68 matched individuals by sex and age in the control group. Binary logistic regression analysis revealed that a history of cardiovascular disease, estimated glomerular filtration rate, and the duration of linezolid therapy were risk factors for hyponatremia. Subgroup analysis in patients age ≥ 65 identified the duration of therapy, a history of cardiovascular disease, a history of endocrine diseases, and serum albumin (ALB) decreased during linezolid therapy as key indicators of hyponatremia. A decrease in ALB during linezolid therapy is a more selective predictor of hyponatremia than baseline ALB. Linezolid-induced hyponatremia is associated with adverse outcomes, highlighting the importance of monitoring serum sodium and ALB in patients receiving this therapy.
- Open Access
- 1 September 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 3901-3911
Retrospective Analysis of Risk Factors for Cefoperazone/Sulbactam-Induced Thrombocytopenia in Adult Chinese Patients: A Six-Year Real-World Study
Background: Drug-induced thrombocytopenia is a rare adverse reaction of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound preparation composed of the third generation of cephalosporin and β-lactamase inhibitor, of which thrombocytopenia is an uncommon but serious adverse reaction. However, the existing literature on cefoperazone/sulbactam-induced thrombocytopenia remains limited, and the specific risk factors associated with this adverse effect have not been thoroughly elucidated. Consequently, this study aims to investigate the clinical characteristics and identify the risk factors for thrombocytopenia in adult patients undergoing cefoperazone/sulbactam therapy. Methods: In this retrospective study, we reviewed patients treated with cefoperazone/sulbactam at Beijing Hospital between January 2017 and June 2023. Patients were categorized into two groups based on the presence or absence of thrombocytopenia: the thrombocytopenia group and the non-thrombocytopenia group. We collected data on demographic features, clinical characteristics, laboratory parameters, treatments, and outcomes. Subsequently, univariate and multivariate logistic regression analyses were performed to identify potential risk factors for cefoperazone/sulbactam-induced thrombocytopenia. Results: In total, 6489 patients were included in this study, and 2.4% (155/6489) developed thrombocytopenia. The results of multivariate analysis showed that cefoperazone/sulbactam therapy duration (d) > 14, PLT (109/L) < 200, daily dose of cefoperazone/sulbactam (g) ≥ 6, TBil (μmoL/L) > 21, AST (U/L) > 35, and use of non-invasive ventilator were risk factors for cefoperazone/sulbactam-induced thrombocytopenia. Conclusion: Despite the low incidence (2.4%), cefoperazone/sulbactam could cause serious thrombocytopenia sometimes accompanied with hemorrhage. In clinical therapy, clinicians should be vigilant in monitoring platelet count, especially for patients with risk factors of cefoperazone/sulbactam-induced thrombocytopenia.
- 1 September 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 3901-3911
Open AccessRetrospective Analysis of Risk Factors for Cefoperazone/Sulbactam-Induced Thrombocytopenia in Adult Chinese Patients: A Six-Year Real-World Study
Background: Drug-induced thrombocytopenia is a rare adverse reaction of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound preparation composed of the third generation of cephalosporin and β-lactamase inhibitor, of which thrombocytopenia is an uncommon but serious adverse reaction. However, the existing literature on cefoperazone/sulbactam-induced thrombocytopenia remains limited, and the specific risk factors associated with this adverse effect have not been thoroughly elucidated. Consequently, this study aims to investigate the clinical characteristics and identify the risk factors for thrombocytopenia in adult patients undergoing cefoperazone/sulbactam therapy. Methods: In this retrospective study, we reviewed patients treated with cefoperazone/sulbactam at Beijing Hospital between January 2017 and June 2023. Patients were categorized into two groups based on the presence or absence of thrombocytopenia: the thrombocytopenia group and the non-thrombocytopenia group. We collected data on demographic features, clinical characteristics, laboratory parameters, treatments, and outcomes. Subsequently, univariate and multivariate logistic regression analyses were performed to identify potential risk factors for cefoperazone/sulbactam-induced thrombocytopenia. Results: In total, 6489 patients were included in this study, and 2.4% (155/6489) developed thrombocytopenia. The results of multivariate analysis showed that cefoperazone/sulbactam therapy duration (d) > 14, PLT (109/L) < 200, daily dose of cefoperazone/sulbactam (g) ≥ 6, TBil (μmoL/L) > 21, AST (U/L) > 35, and use of non-invasive ventilator were risk factors for cefoperazone/sulbactam-induced thrombocytopenia. Conclusion: Despite the low incidence (2.4%), cefoperazone/sulbactam could cause serious thrombocytopenia sometimes accompanied with hemorrhage. In clinical therapy, clinicians should be vigilant in monitoring platelet count, especially for patients with risk factors of cefoperazone/sulbactam-induced thrombocytopenia.